Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease

Ultrasonic Imaging

Volumn 38, Issue 3, 2016, Pages 225-235

  Ozveren, Olcay ^a   Izgi, Cemil ^b   Eroglu, Elif ^a   Simsek, Mustafa Aytek ^a   Turer, Ayca ^a   Kucukdurmaz, Zekeriya ^a   Cinar, Veysel ^a   Degertekin, Muzaffer ^a  

^a YEDITEPE UNIVERSITY   (Turkey)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

atrial conduction; atrial fibrillation; electromechanical delay; left atrium; non alcoholic fatty liver disease; P wave dispersion

Indexed keywords

CARDIOLOGY; DISEASES; DISPERSION (WAVES); ECHOCARDIOGRAPHY; SEISMIC WAVES; TISSUE;

ATRIAL FIBRILLATION; ELECTROMECHANICAL DELAYS; LEFT ATRIUMS; NON-ALCOHOLIC FATTY LIVER DISEASE; P WAVES;

DIAGNOSIS;

ADULT; ATRIAL FIBRILLATION; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY;

ADULT; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84963553685     PISSN: 01617346     EISSN: 10960910     Source Type: Journal    
DOI: 10.1177/0161734615595015     Document Type: Article

References (29)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G,. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53: 372-84.
2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129: 113-21.
3. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G,. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 1724-45.
4. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24: 663-9.
5. Liu YC, Hung CS, Wu YV, Lee YC, Lin YH, Lin C, et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2013; 8: e61803.
6. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013; 125: 301-9.
7. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013; 8: e57183.
8. Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013; 111: 219-24.
9. Ying I, Saposnik G, Vermeulen MJ, Leung A, Ray JG,. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology. 2011; 22: 129-30.
10. Dilaveris PE, Gialafos JE,. P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol. 2001; 6: 159-65.
11. Chao TF, Sung SH, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Associations between the atrial electromechanical interval, atrial remodelling and outcome of catheter ablation in paroxysmal atrial fibrillation. Heart. 2011; 97: 225-30.
12. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F,. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51: 433-45.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7: 79-108.
14. Sengul C, Cevik C, Ozveren O, Sunbul A, Oduncu V, Akgun T, et al. Acute alcohol consumption associated with increased interatrial electromechanical delay in healthy men. Cardiol J. 2011; 18: 682-6.
15. Ozer N, Yavuz B, Can I, Atalar E, Atalar E, Aksöyek S, Ovünç K, et al. Doppler tissue evaluation of intraatrial and interatrial electromechanical delay and comparison with P wave dispersion in patients with mitral stenosis. J Am Soc Echocardiogr. 2005; 18: 945-8.
16. Makar GA, Weiner MG, Kimmel SE, Bennett D, Burke A, Yang YX, et al. Incidence and prevalence of abnormal liver enzymes in patients with atrial fibrillation in routine clinical care population. Pharmacoepidemiol Drug Saf. 2008; 17: 43-51.
17. Alonso A, Misialek JR, Amiin MA, Hoogeveen RC, Chen LY, Agarwal SK, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart. 2014; 100 (19): 1511-6. doi: 10.1136/heartjnl-2014-305756.
18. Clark JM, Brancati FL, Diehl AM,. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 960-7.
19. Deftereos S, Kossyvakis C, Efremidis M, Bouras G, Panagopoulou V, Papadimitriou C, et al. Interatrial conduction time and incident atrial fibrillation: a prospective cohort study. Heart Rhythm. 2014; 11: 1095-101.
20. Dorian P, Singh BN,. Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl. 2008; 10: H11-31.
21. Nielsen JB, Pietersen A, Graff C, Lind B, Struijk JJ, Olesen MS, et al. Risk of atrial fibrillation as a function of electrocardiographic PR interval: results from the Copenhagen ECG Study. Heart Rhythm. 2013; 10: 1249-56.
22. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006; 40: 949-55.
23. Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I,. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am J Cardiol. 2013; 112: 436-43.
24. Paschos P, Tziomalos K,. Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment. World J Hepatol. 2012; 4: 327-31.
25. Emilsson L, Smith JG, West J, Melander O, Ludvigsson JF,. Increased risk of atrial fibrillation in patients with coeliac disease: a nationwide cohort study. Eur Heart J. 2011; 32: 2430-7.
26. Peña JM, MacFadyen J, Glynn RJ, Ridker PM,. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012; 33: 531-7.
27. Tsioufis C, Syrseloudis D, Hatziyianni A, et al. Relationships of CRP and P wave dispersion with atrial fibrillation in hypertensive subjects. Am J Hypertens. 2010; 23: 202-7.
28. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008; 16: 1394-9.
29. Hung CL, Chao TF, Lai YH, Yen C-H, Wang K-L, Tsao H-M, et al. The relationship among atrium electromechanical interval, insulin resistance, and metabolic syndrome. Can J Cardiol. 2013; 29: 1263-8.